ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014
Incorporating biomarkers into cancer and aging research.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 77 citations in OpenAlex.
- Protein profiling reveals consequences of lifestyle choices on predicted biological aging.Scientific reports · 2015Trial
- Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers.Cancer medicine · 2025Review
- Gerotherapeutics: aging mechanism-based pharmaceutical and behavioral interventions to reduce cancer racial and ethnic disparities.Journal of the National Cancer Institute · 2025Review
- The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study.Frontiers in oncology · 2025Article
- Association Between Changes in Skeletal Muscle Quality and Prognosis in Postoperative Patients with Early Gastric Cancer.Annals of surgical oncology · 2024Article
- Progress in the study of aging marker criteria in human populations.Frontiers in public health · 2024Review
- Epigenetic and inflammatory markers in older adults with cancer: A Young International Society of Geriatric Oncology narrative review.Journal of geriatric oncology · 2024Review
- Article
- Effects of systemic inflammation and frailty on survival in elderly cancer patients: Results from the INSCOC study.Frontiers in immunology · 2023Article
- The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study.Journal of clinical medicine · 2022Article
- A nomogram for predicting cancer-specific survival and overall survival in elderly patients with nonmetastatic renal cell carcinoma.Frontiers in surgery · 2022Article
- Applying a Life Course Biological Age Framework to Improving the Care of Individuals With Adult Cancers: Review and Research Recommendations.JAMA oncology · 2021Review
- Breast-Specific Molecular Clocks Comprised ofCancer prevention research (Philadelphia, Pa.) · 2021Article
- Measuring Biologic Resilience in Older Cancer Survivors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer.Cancers · 2021Article
- Association of Postoperative Biomarker Response with Recurrence and Survival in Patients with Hepatocellular Carcinoma and High Alpha-Fetoprotein Expressions (>400 ng/ml).Journal of hepatocellular carcinoma · 2021Article
- The Resistance ofAntioxidants (Basel, Switzerland) · 2020Article
- Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker,JNCI cancer spectrum · 2020Article
- p16 a biomarker of aging and tolerance for cancer therapy.Translational cancer research · 2020Review
- Sarcopenia in aging, obesity, and cancer.Translational cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The challenge in treating the older adult with cancer is accurately accounting for and adapting management to the heterogeneity in health status of the individual patient. Many oncologists recognize that chronological age alone should not be the determinant when deciding on a treatment regimen. Easily measurable markers that provide an assessment of functional age would be ideal to assess frailty, which may predispose the patient to complications from cancer treatment, including increased toxicity, functional decline, decreased quality of life, and poorer survival. Several categories of potential markers, including chronic inflammatory markers, markers of cellular senescence, and imaging to assess muscle mass to detect sarcopenia, may provide insight into the likelihood of treatment-related complications. This article discusses candidate markers and strategies to evaluate these markers in cancer treatment trials, with the aim of developing a method to assess risk of oncologic outcomes and guide management decisions for both the physician and patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.